HAWKEYE BIO

Hawkeye Bio is developing patented nanoscale biosensors (NBS) for disease detection. The company's lead clinical program in oncology is focused on the deployment of nanobiosensors to non-invasively detect early stage cancer. Identifying cancer reliably, safely, and affordably at the earliest stage is critical for successful treatment and survival. The NBS are also being evaluated to monitor patients post-treatment to identify cases of minimal residual disease and intercept recurrence. The NBS platform is also being clinically evaluated for applications in infectious and autoimmune disease.